REPLIGEN CORP (RGEN)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for RGEN
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| RGEN | Director, Chair of the Board | 66 | ["Public Company Board/CEO", "Risk Oversight", "Manufacturing & Global Operations", "Strategic Planning and M&A", "Life Sciences Technology & Innovation", "Commercial Sales & Marketing"] | [] | 2026 |
Biography sourced from the proxy statement filing.
Currently serving as the Chair of the Board, succeeded Tony J. Hunt, following his previously announced retirement in March 2026. The Board has determined Dr. Madaus is an independent member of the Board under the rules and regulations of the Securities and Exchange Commission and the Nasdaq Stock Market. Currently serves as Chairperson of the Nominating and Corporate Governance Committee. Member of the Nominating and Corporate Governance Committee. The Board has determined that Dr. Madaus is independent within the meaning of the SEC's and Nasdaq's director independence standards.